2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights

Affiliations

• 1 Department of Chemistry, Graduate School of Science, Hiroshima University, Hiroshima, Japan.
• 2 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
• 3 Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
• 4 Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
• 5 Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
• 6 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The British University in Egypt (BUE), Cairo, Egypt.
• 7 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
• 8 Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
• 9 Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia.
• 10 Department of Medicine, University of California San Diego, La Jolla, CA, USA.
• 11 Moores Comprehensive Cancer Center, University of California San Diego, La Jolla, CA, USA.
• 12 Veterans Affairs Medical Center, La Jolla, CA, USA.